-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

Benzinga·09/09/2026 12:12:17
Listen to the news
Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.